ArticleBioinformation2020
Towards Neuro-CoViD-19.
Article in Bioinformation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Memory, Emotion, and Quality of Life in Patients with Long COVID-19.Brain sciences · 2023Article
- ACE2 Receptor and TMPRSS2 Protein Expression Patterns in the Human Brainstem Reveal Anatomical Regions Potentially Vulnerable to SARS-CoV-2 Infection.ACS chemical neuroscience · 2023Article
- Shared miRNA landscapes of COVID-19 and neurodegeneration confirm neuroinflammation as an important overlapping feature.Frontiers in molecular neuroscience · 2023Article
- Changes in Electrical Brain Activity and Cognitive Functions Following Mild to Moderate COVID-19: A one-Year Prospective Study After Acute Infection.Clinical EEG and neuroscience · 2022Article
- Cognitive impairment in people with previous COVID-19 infection: A scoping review.Cortex; a journal devoted to the study of the nervous system and behavior · 2022Article
- Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson's Disease: A Narrative Review.Brain sciences · 2022Review
- Chronic neuropsychiatric sequelae of SARS-CoV-2: Protocol and methods from the Alzheimer's Association Global Consortium.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Editorial: Neuro-covid: neuropsychological implications of the pandemic.Frontiers in psychology · 2022Article
- Mindfulness Meditation Interventions for Long COVID: Biobehavioral Gene Expression and Neuroimmune Functioning.Neuropsychiatric disease and treatment · 2022Review
- Post acute CoViD-19 syndrome (PACS) - Long CoViD.Bioinformation · 2022Article
- Electrophysiological and olfactometric evaluation of long-term COVID-19.Physiological reports · 2021Article
- Cellular mechanisms underlying neurological/neuropsychiatric manifestations of COVID-19.Journal of medical virology · 2021Review
- Chemosensory Systems in COVID-19: Evolution of Scientific Research.ACS chemical neuroscience · 2021Review
- Current opinion in neurological manifestations of SARS-CoV-2 infection.Current opinion in toxicology · 2021Review
- The Impact of the COVID-19 Pandemic on Dementia Risk: Potential Pathways to Cognitive Decline.Neuro-degenerative diseases · 2021Review
- Aging in COVID-19: Vulnerability, immunity and intervention.Ageing research reviews · 2021Review
- Long-Term Respiratory and Neurological Sequelae of COVID-19.Medical science monitor : international medical journal of experimental and clinical research · 2020Review
- Applications of Non-invasive Neuromodulation for the Management of Disorders Related to COVID-19.Frontiers in neurology · 2020Review
- Putative Natural History of CoViD-19.Bioinformation · 2020Article
- Neuroinvasive potential of a primary respiratory pathogen SARS- CoV2: Summarizing the evidences.Diabetes & metabolic syndromeReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CoViD-19 is the current pandemic caused by the Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2). Infection by SARS-CoV-2 occurs via the binding of its S protein to the angiotensin-converting enzyme-2 receptor (ACE2-R). S binding to ACE2-R leads to a drop in ACE2, a homolog of angiotensin converting enzyme (ACE). In the central nervous system (CNS), ACE mediates neuroinflammation, neurodegeneration and neurotoxicity responsible for several CNS disorders. ACE2 counteracts the damaging effects of ACE on CNS neurons. SARS-CoV-2 can directly access the CNS via the circulation or via cranial nerve I and the olfactory bulb. Inactivation of ACE2 following binding of SARS-CoV-2 S protein to ACE2-R in situ might blunt ACE2-moderating effects upon ACE CNS neurotoxicity and neurodegeneration. Here, we propose a neurobiological mechanism directly involving SARS-CoV-2 binding to ACE2-R in the etiology of putative Neuro-CoViD-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.